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Abstract
It has been proposed that a reduction in intracellular calcium causes an increase in intracel-
lular cAMP and PKA activity through stimulation of calcium inhibitable adenylyl cyclase 6
and inhibition of phosphodiesterase 1 (PDE1), the main enzymes generating and degrading
cAMP in the distal nephron and collecting duct, thus contributing to the development and
progression of autosomal dominant polycystic kidney disease (ADPKD). In zebrafish pde1a
depletion aggravates and overexpression ameliorates the cystic phenotype. To study the
role of PDE1A in a mammalian system, we used a TALEN pair to Pde1a exon 7, targeting
the histidine-aspartic acid dipeptide involved in ligating the active site Zn++ ion to generate
two Pde1a null mouse lines. Pde1a mutants had a mild renal cystic disease and a urine con-
centrating defect (associated with upregulation of PDE4 activity and decreased protein
kinase A dependent phosphorylation of aquaporin-2) on a wild-type genetic background and
aggravated renal cystic disease on a Pkd2WS25/- background. Pde1a mutants additionally
had lower aortic blood pressure and increased left ventricular (LV) ejection fraction, without
a change in LV mass index, consistent with the high aortic and low cardiac expression of
Pde1a in wild-type mice. These results support an important role of PDE1A in the renal path-
ogenesis of ADPKD and in the regulation of blood pressure.
Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is the fourth leading cause of end-
stage kidney disease. It is caused by mutations in PKD1 or PKD2 encoding polycystin 1 and
polycystin 2 [1, 2]. Substantial evidence supports the hypothesis that disruption of polycystin
function results in dysregulation of intracellular calcium dynamics and upregulation of 3’,5’-
cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA) signaling [3–5]. The
identification of cAMP and PKA signaling as a therapeutic target [6–9] has led to clinical trials
of vasopressin V2 receptor (V2R) antagonists and somatostatin analogs [10, 11] and to the
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Further understanding of the mechanisms responsible for the increased cAMP signaling in
PKD may provide additional therapeutic opportunities. It has been proposed that the increase
in cAMP signaling is, in part, a direct consequence of a reduction in intracellular calcium
homeostasis through the inhibition of phosphodiesterase (PDE)-1, the only PDE activated by
calcium [6]. The PDE1 family consists of three isoforms encoded by three distinct genes,
PDE1A, PDE1B and PDE1C. We have shown that pde1a interference using splice- and transla-
tion-blocking morpholinos causes pronephric cysts, hydrocephalus, and body curvature in
wild-type zebrafish embryos and aggravates the cystic phenotype in pkd2 morphants, while
human PDE1A RNA partially rescues the pde1a and pkd2 morphant phenotypes [12]. To study
the role of PDE1A in a mammalian system we created Pde1a null mouse lines using TALENs.
Methods
The Mayo Clinic Institutional Animal Care and Utilization Committee approved all experi-
mental protocols for the work described within this report.
Targeted disruption of Pde1a
We used a TALEN pair to Pde1a exon 7 (NM_001159582.1 mouse chromosome 2). This exon
was selected because it is the second exon in the catalytic domain and contains a histidine-
aspartic acid dipeptide involved in the coordination of a Zn++ ion required for catalytic activity
[13] (Fig 1A). We injected a total of 100 C57BL6/J oocytes, recovered 40 pups of which at least
5 males and 3 females harbored a mutation.
Genotyping and breeding of Pde1a and Pkd2 mutant mice
Pde1a (Fig A in S1 File) and Pkd2 genotyping by PCR and Southern blot are described in the
Supplemental material. Pde1aDel15/Del15, Pkd2+/- and Pkd2WS25/WS25 mice were crossed to gen-
erate Pde1aDel15/Del15;Pkd2-/WS25 and Pde1a+/+;Pkd2-/WS25 mice.
Phenotypic characterization of Pde1a mutant mice
Litter sizes, blood and urine biochemistries and magnetic resonance imaging (MRI) of the
abdomen and/or heart were obtained at 6 and 12 months in Pde1a mutant and wild-type mice.
Urinary concentrating ability and the capacity to excrete a water load were tested at 12 months
of age. Echocardiogram, aortic blood pressure and histology of Pde1aDel15/Del15 and Pde1aInsA/
InsA were compared to those of sex and age matched wild-type controls.
Treatment with desmopressin
Desmopressin (30 ng/100 g/hour) or saline vehicle was administered subcutaneously via
osmotic minipumps (Alzet 1004 replaced every 3 wk) to wild-type and Pde1aInsA/InsA mice, or
to wild-type;Pkd2-/WS25 and Pde1aDel15/Ddel15;Pkd2-/WS25 mice between 4 and 16 weeks of age.
Abdominal and cardiac MRI
Ultra high field (UHF) abdominal and cardiac MRI images were acquired as described in the
supplemental material (https://www.jove.com/video/52757/use-ultra-high-field-mri-small-
rodent-models-polycystic-kidney).
Pde1a mouse knockout
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Blood collections and tissue harvesting
Blood was obtained by cardiac puncture under ketamine (60mg/kg i.p.) and xylazine (10mg/
kg i.p.) anesthesia. The right kidney and part of the liver were placed into preweighed vials
containing 10% formaldehyde in phosphate buffer. The left kidney was immediately frozen in
liquid nitrogen. Hearts were cut transversally and the apex was frozen immediately in liquid
nitrogen while the rest was placed into vials containing 10% formaldehyde.
PDE activities
PDE activities in the kidneys and heart were measured as described in the Supplemental Material.
Specific activities were expressed as picomoles of cAMP hydrolyzed per minute/mg of protein.
cAMP and cGMP content
The cAMP and cGMP were assessed by enzyme-linked immunosorbent assay (Enzo Life Sci-
ences, Farmingdale, NY). Results were expressed in pmol/mg of protein.
Western blots
Immunoblotting of kidney and heart lysates or cytosol was performed as described in the Sup-
plemental Material. Antibodies used were: PDE1A (12442-2-AP, Proteintech, Rosemount IL);
Fig 1. A) Left and right TALENs designed to disrupt exon 7 of mPde1a (active site). B) Recovered mutations include an in-frame 15bp deletion and insertion
of a single A. C) Effect on mPde1a protein, the 15bp in frame deletion (760_774) removes amino acids FAAAI and the insertion of an A (765_766) truncates
mPde1a after four out of frame amino acids. D) Western blot of N-terminal V5-tagged wild-type and mutant mPde1a expressed in Xenopus oocytes detected
with V5 antibody. E) PDE1 activity (Ca2+/calmodulin dependent hydrolysis of cAMP) in Xenopus oocytes injected with water, wild-type RNA or mutated
RNAs. F) Western blot of kidney lysates showing a 64 kDa protein in wild-type mice (arrow) detected with a rabbit polyclonal antibody raised against
recombinant human PDE1A (360 C-terminal amino acids); this band was markedly reduced in Pde1aDel15 and absent in Pde1aInsA homozygous mice. G)
Reverse transcription of kidney RNA, PCR amplification and PvuII-HF restriction endonuclease digestion of a 485 bp PCR product, showing a 327 bp
fragment in the wild-type and a 420 bp fragment in the mutants (smaller digest fragments are not resolved).
https://doi.org/10.1371/journal.pone.0181087.g001
Pde1a mouse knockout
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PDE1B (ab14600, Abcam, Cambridge, MA); PDE1C (sc67323, Santa Cruz, CA); pSer269--
AQP2 (ab110418, Abcam, MA). The membrane was stained using swift membrane stain kit
and total protein stain was used as loading control [14].
RT-PCR of tissue RNA
1μg of total RNA was reverse transcribed using SuperScript First-Strand Synthesis System
(Invitrogen) in a total volume of 20μl at 37˚C for 1hour. The PCR reactions were performed
with 200nM mouse Pde1a specific primers: Forward: 5’-ATGCAGCTGACGTCACTCAA,
Reverse: 5’- AGGGCCATGGTCCATCTGTA for 30 cycles at 95˚C for 40s, 60˚C for 1min and
72˚C for 1min. 10μl of the PCR products were digested with 10μl of a digest master mix using
0.3μl of PvuII-HF per reaction and digested overnight. The uncut PCR product is 484 bp.
PvuII cut the PCR product to generate fragments of 327+93+58+6 bp in wild-type and 420+58
+6 bp in PDE1aDel15 and PDE1aInsA.
Histomorphometric and immunohistochemical analyses
These were performed as described in the Supplemental material. Antibodies used were
against lysozyme (ab108508, Abcam, Cambridge, MA), Tamm-Horsfall protein (THP,
sc20631, Santa Cruz, CA), aquaporin-2 (AQP2, sc9882, Santa Cruz, CA), epithelial membrane
antigen (EMA, MA5-11202, Thermo Scientific, Rockford, IL), and proliferating cell nuclear
antigen (PCNA, sc-56, Santa Cruz, CA).
Statistical analysis
Data are expressed as means ± SD. One-way analysis of variance (ANOVA) with post-hoc
Tukey test is used for comparisons between groups. The Student’s t-test was used for compari-
sons between two groups.
Results
Pde1a mutants
Of eight pups carrying Pde1a mutations, we focused on an in frame deletion of 15bp, c.760-774del
p.Phe254-Ile258del deleting amino acids FAAAI in the active site of mPDE1A (Pde1aDel15) and an
A insertion in the same region c.765-766insA p.Ala255fs5X which caused a frame shifting muta-
tion that terminated the open reading frame after 4 out of frame amino acids (Pde1aInsA) (Fig 1B
and 1C). V5-tagged wild-type, Pde1aDel15 and Pde1aInsA RNAs were injected into Xenopus
oocytes. Western blotting with a V5 antibody showed a 64 kDa protein in the oocytes injected
with the wild-type or Pde1aDel15 RNA and a truncated 30 kDa protein in oocytes injected with the
Pde1aInsA RNA (Fig 1D). In contrast to wild-type RNA, mutated RNAs failed to generate calcium/
calmodulin dependent enzymatic activity when injected into Xenopus oocytes (Fig 1E). Western
blot analysis of kidney lysates from wild-type mice with a PDE1A polyclonal antibody showed a
64 kDa protein, which was markedly reduced in Pde1aDel15 and absent in Pde1aInsA mice (Fig 1F).
Reverse transcription of kidney RNA, PCR amplification and PvuII-HF restriction endonuclease
digestion of the 485 bp PCR product showed 6, 59, 93, and 327 bp fragments in the wild-type 6,
59, and 420 bp fragments in the mutants, confirming the genotyping results (Fig 1G).
Characteristics of Pde1a knockout mice
The Pde1a alleles were produced on an inbred B57BL/6J background, identical to the back-
ground used to inbreed our PKD models. Male and female Pde1a mutant mice were fertile. Lit-
ter sizes, general appearance and pre-weaning or post-weaning growth of homozygous or
Pde1a mouse knockout
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heterozygous Pde1aDel15 or Pde1aInsA were not different from wild-type mice. At 12 months of
age, kidney to body weight ratios were not different between Pde1aDel15/Del15 and Pde1aInsA/
InsA mice but both were significantly higher compared to the wild-type mice, whereas body
weights, weights of other organs, and blood chemistries were similar (Table 1). Subsequently,
both the homozygous Pde1aDel15 and Pde1aInsA mice were considered as null models.
Activity and expression of PDE1, PDE3 and PDE4 families and cAMP
levels in kidneys and hearts from Pde1aDel15 and Pde1aInsA
homozygotes compared to wild-type mice
In kidney tissue total PDE and PDE1 activities were reduced, whereas PDE3 and PDE4 activities
were increased in both, Pde1aDel15/Del15 mice, as previously reported in younger animals[15],
and in Pde1aInsA/InsA mice compared to wild-type controls (Fig 2A). Total PDE, PDE1 and
PDE3 activities were higher in the hearts than in the kidneys. In contrast to the kidneys, cardiac
PDE1 activities were not lower and PDE3 and PDE4 activities were not higher in either model
compared to wild-type mice. Expression of PDE1A protein was lower and expressions of PDE1B
and PDE1C proteins were higher in hearts compared to kidneys of wild-type mice (Fig 2B).
Renal cAMP levels tended to be higher in the kidneys but not in the hearts of Pde1a mutants
compared to control animals (Fig 2C). Renal and cardiac cGMP levels in the Pde1a mutant and
wild-type mice were not different (Fig 2C). PDE1A protein was expressed at higher levels in the
aorta compared to the heart, with the highest level of expression being in the brain (Fig 2D).
Pde1a null mice developed mild renal cystic disease
At sacrifice the Kidney to body weight ratios of the Pde1aInsA/InsA and Pde1aDel15/Del15 homo-
zygous mice were higher than those of wild-type mice (Table 1, Fig 3A). MR scans of the
Table 1. Body and organ weights and laboratory parameters at 12 months of age.
Wild-type
(10 M, 9 F)
Pde1aInsA/InsA
(9 M, 9 F)
Pde1aDel15/Del15
(12 M, 19 F)
Pde1aInsA/InsA or Del15/Del15
(21 M, 28 F)
Body weight, g 29.4±5.3 29.2±3.6 28.7±3.7 28.9±3.7
Kidney weight, g 0.42±0.08 0.45±0.06 0.47±0.09 0.46±0.08
Kidney weight, % BW 1.44±0.11 1.54±0.13* 1.63±0.26‡ 1.60±0.22‡
Liver weight, g 1.48±0.31 1.32±0.23 1.40±0.30 1.37±0.28
Liver weight, % BW 5.03±0.57 4.56±0.79 4.88±0.72 4.76±0.76
Heart weight, g 0.18±0.05 0.20±0.03 0.20±0.04 0.20±0.12
Heart weight, % BW 0.63±0.10 0.68±0.12 0.69±0.11 0.69±0.12
Spleen weight, g 0.09±0.05 0.11±0.04 0.11±0.04 0.11±0.04
Spleen weight, % BW 0.34±0.13 0.39±0.19 0.38±0.14 0.38±0.16
Lung weight, g 0.22±.04 0.23±0.04 0.25±0.04 0.24±0.04
Lung weight, % BW 0.78±0.18 0.81±0.20 0.88±0.18 0.86±0.19
Serum sodium, mEq/L 152.9±4.5 149.1±3.8 151.3±4.4 150.5±4.3
Serum potassium, mEq/L 7.1±0.9 7.0±1.1 7.3±1.1 7.2±1.1
Serum glucose, mg/dL 174±27 207±32 171±28 185±34
Serum creatinine, mg/dL 0.47±0.24 0.49±0.15 0.53±0.17 0.51±0.61
vs wild-type
*p<0.05
‡p<0.001.
BW: Body weight
https://doi.org/10.1371/journal.pone.0181087.t001
Pde1a mouse knockout
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kidneys were obtained at 6 and 12 months of age. At these ages small renal cysts were ob-
served in 9 of 19 (47%, 8 Pde1aDel15/Del15 and 11 Pde1aInsA/InsA mice) and 17 of 27 (63%,
20 Pde1aDel15/Del15 and 7 Pde1aInsA/InsA mice) Pde1a mutant compared to 1 of 12 (13%,
P = 0.046) and 1 of 10 (10%, P = 0.008) wild-type mice, respectively (Fig 3B and Fig B in S1
File). Histological examination of the kidneys at 12 months of age confirmed the presence of
small cortical and medullary cysts and tubular dilatation in 26 of 44 (59%, 26 Pde1aDel15/Del15
and 18 Pde1aInsA/InsA mice) Pde1a mutant compared to 3/18 (17%, P = 0.004) wild-type mice
(P<0.001). Only one or two small cysts confined to the inner medulla were observed in the
three wild-type mice. MR and tissue sections showing small cysts in 12 month old wild-type
mice are shown in Fig C in S1 File. Most dilated tubules and microscopic cysts stained positive
with Tamm-Horsfall protein (THP, a marker for the thick ascending limb of Henle) and/or
Fig 2. A) Total PDE, PDE1, PDE3 and PDE4 activities in kidney and heart lysates from wild-type mice and from Pde1aDel15 and Pde1aInsA homozygous
mice or results of both combined. B) Western blots of kidney and heart lysates from six wild-type mice detected with PDE1A, PDE1B and PDE1C
antibodies; total protein stain with Coomassie Blue is used as a loading control. C) Cyclic AMP and cGMP levels in kidney and heart lysates from wild-type
mice and from Pde1aDel15 and Pde1aInsA homozygous mice or results of both combined. D) Western blot of kidney, heart, aorta, liver, spleen and brain
lysates from wild-type and Pde1aInsA homozygous mice detected with a PDE1A antibody; a weak cardiac band can be seen in wild-type with longer
exposure (data not shown). One-way ANOVA with post-hoc Tukey test was used for the statistical analysis.
https://doi.org/10.1371/journal.pone.0181087.g002
Pde1a mouse knockout
PLOS ONE | https://doi.org/10.1371/journal.pone.0181087 July 27, 2017 6 / 19
epidermal membrane antigen (EMA, a marker for the distal nephron and collecting ducts),
less often with aquaporin-2 (AQP-2, a marker for collecting duct principal cells), and were
consistently negative for lysozyme (a proximal tubule marker; Fig 3C). Many cells in dilated
tubules and microscopic cysts stained positive for PCNA (Fig 4).
Pde1a knockout mice had impaired urine concentrating capacity
The pool of cAMP generated in response to vasopressin is mainly hydrolyzed by PDE1 and the
accumulation of cAMP in response to vasopressin is markedly increased when intracellular
calcium is reduced, mainly due to lower PDE1 activity [16, 17]. We therefore anticipated that
Pde1a knockout mice would have an enhanced urine concentrating capacity and impaired
Fig 3. A) Body weight and kidney weight as percent of body weight (%KW/BW) in wild-type mice and in Pde1aDel15 and Pde1aInsA homozygous mice or
data from both combined. B) Axial and coronal MR images of Pde1a mutant mice at 6 and 12 months of age showing small renal cysts (arrows; this panel is
also shown as a larger figure in Fig B in S1 File). C) Kidney sections from Pde1aDel15 and Pde1aInsA homozygous mice showing multiple small cysts staining
positively for Tamm-Horsfall protein and epithelial membrane antigen, less consistently for aquaporin-2, and not staining for lysozyme. D) Reduced urine
osmolality after 24 hours of dehydration, faster excretion of an acute water load, and E) reduced expression of glycosylated (upper band) and unglycosylated
(lower band) pSer269-AQP2 in Pde1aDel15 and Pde1aInsA homozygotes compared to wild-type mice. One-way ANOVA with post-hoc Tukey test was used for
the statistical analysis.
https://doi.org/10.1371/journal.pone.0181087.g003
Pde1a mouse knockout
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diluting capacity. Contrary to this expectation, we found that at 12 months of age these mice
had a mild urine concentration defect after 24 hrs dehydration (3375±312 and 3394±273 com-
pared to 4057±255 mOsm/L in wild-type, P<0.01, Fig 3D) and were able to excrete a water
load faster (54±29 and 77±35 compared to 37±25% of 2 ml ip over 6 hrs in wild-type mice,
P<0.01, Fig 3D). Since PDE4D controls a cAMP pool that regulates the expression, phosphor-
ylation and translocation of AQP2 to the apical membrane of the collecting duct principal cells
[18] and constitutive activation of PDE4 was found to be responsible for a mouse model of
nephrogenic diabetes insipidus [19], we wondered whether the increased activity of PDE4 in
the kidneys of the Pde1a mutants could be responsible for the mild concentration defect
observed in these mice. Consistent with this, the expression of pSer269-AQP2 was decreased
Fig 4. PCNA immunostaining of kidney sections (x 200) in wild-type mice (n = 4) and in Pde1aDel15 (n = 5) or Pde1aInsA (n = 3) homozygous mice,
and both combined (n = 8). Proliferative indices were significantly higher in the Pde1a mutants compared to the wild type mice. One-way ANOVA with
post-hoc Tukey test was used for the statistical analysis.
https://doi.org/10.1371/journal.pone.0181087.g004
Pde1a mouse knockout
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in the kidneys of Pde1aDel15 and Pde1aInsA homozygous mice compared to those of wild-type
controls (Fig 3D).
Effect of desmopressin administration on the renal phenotype of
Pde1aInsA/InsA mice
The administration of desmopressin enhances the development of renal cystic disease in PCK
rats and in Pkd1RC/RC and Pkd2WS25/- mice [8, 20]. To determine whether it could induce the
development of renal cystic disease in Pde1a mutant mice, desmopressin (DDAVP, 30 ng/100
g BW/hr subcutaneously) or saline was administered to Pde1aInsA homozygous and wild-type
mice (5 male and 5 female mice per genotype and treatment) between 4 and 16 weeks of age.
At 16 weeks of age the kidney to body weight ratios of desmopressin-treated Pde1a mutant
mice were higher than those of saline-treated wild-type mice (Fig 5A). Two-way ANOVA
showed that both Pde1a null genotype P<0.001) and desmopressin treatment (P = 0.004) were
associated with higher kidney to body weight ratios. Additionally, cAMP levels were higher in
desmopressin-treated Pde1a mutant mice compared to control mutant and both wild-type
groups. Prior to sacrifice, MRI of the kidneys were obtained in five Pde1aInsA and four wild-
type mice treated with desmopressin; three of the mutant and none of the wild-type mice had
renal cysts (2–3 per animal, Fig 5A). Histological examination confirmed the presence of
microscopic cysts staining positive for THP, EMA and less consistently AQP2 (Fig 5A).
Fig 5. A) Upper panels: Kidney weights as percent of body weights (%KW/BW) and renal cAMP levels in untreated or desmopressin treated
wild-type and Pde1aInsA homozygous mice (upper panels); One-way ANOVA with post-hoc Tukey test was used for the statistical analysis; using
a two-way ANOVA, both Pde1a null genotype P<0.001) and desmopressin treatment (P = 0.004) were associated with higher kidney to body
weight ratios. Lower panels: Kidney sections stained with hematoxylin-eosin or immunostained with Tamm-Horsfall protein, epithelial membrane
antigen or aquaporin-2 antibodies, and coronal MR image showing small cysts (arrows) in desmopressin treated Pde1aInsA homozygous mice. B)
%KW/BW, kidney cystic indices, renal cAMP levels, and kidney sections stained with hematoxylin-eosin in untreated or desmopressin treated
Pkd2-/WS25 and Pkd2-/WS25;Pde1aDel15/Del15 mice. One-way ANOVA with post-hoc Tukey test was used for the statistical analysis.
https://doi.org/10.1371/journal.pone.0181087.g005
Pde1a mouse knockout
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The development of polycystic kidney disease in Pkd2-/WS25 mice was
enhanced on a Pde1a null genetic background and aggravated by the
administration of desmopressin
We previously reported that the development of PKD in Pkd2-/WS25 mice is aggravated on a
Pde1a or a Pde3a null background [15]. We also suggested that the lower susceptibility to PKD
and enhanced disease associated with desmopressin treatment, when comparing mice to rats,
may be due to higher PDE activities in mouse compared to rat kidneys [20, 21]. Indeed we
found that administration of desmopressin aggravated the renal cystic disease of Pkd2-/WS25
mice on a Pde3a null background compared desmopressin-treated Pkd2-/WS25 mice on a wild-
type background [15]. To determine whether the cystogenic effects of desmopressin would
also be enhanced on a Pde1a null background, we administered desmopressin (30 ng/100 g
BW per hour subcutaneously) or saline to Pkd2-/WS25;Pde1aDel15/Del15 and Pkd2-/WS25 mice.
Kidney to body weight ratios and cystic indices were significantly higher in desmopressin-
treated Pkd2-/WS25 mice on a Pde1a null background compared to saline- or desmopressin-
treated Pkd2-/WS25 mice on a wild-type background (Fig 5B). Kidney to body weight ratios
KWand cystic indices were numerically higher in desmopressin-treated compared to saline-
treated Pkd2-/WS25 mice on a Pde1a null background, without reaching statistical significance
(P = 0.054 and 0.20, respectively).
Pde1a knockout mice have a cardiovascular phenotype
Because of the association of various cardiac phenotypes with PKD [22, 23] and the finding that
PDE1 accounts for a major component of PDE activity in the heart, we tested whether inactiva-
tion of Pde1a results in a cardiac or cardiovascular phenotype. We found that both Pde1aDel15
and Pde1aInsA mice had lower aortic blood pressures (Fig 6A) and higher LV ejection fractions
on echocardiography (Fig 6B) compared to wild-type mice. However, there was no difference
in LV mass index measured by MRI between Pde1a wild-type and mutant mice (Fig 6C).
Discussion
A substantial body of evidence indicates that cAMP and PKA signaling play a central role in
PKD [3–5]. It has been proposed that a reduction in intracellular calcium causes the upregula-
tion of cAMP and PKA through stimulation of calcium inhibitable adenylyl cyclase 6 and inhi-
bition of PDE1, the main enzymes generating and degrading cAMP in the distal nephron and
collecting duct [6]. Consistent with this hypothesis, a collecting duct-specific knockout of ade-
nylyl cyclase 6 affords protection in a Pkd1 mouse model [24]. Since capacity for hydrolysis of
cyclic nucleotides by PDEs far exceeds that for synthesis by adenylyl cyclases [25], modulation
of PDE activity, particularly PDE1 activity, may be crucial in PKD.
PDE1 is one of eleven mammalian PDE families (PDE1-PDE11) with twenty-two genes
and close to 100 distinct isoenzyme variants generated through the use of alternate promoter
initiation sites and/or alternate splicing [26, 27], PDE family members may exclusively hydro-
lyze cAMP or cGMP, or they may hydrolyze both. PDE activities are regulated by phosphory-
lation/dephosphorylation (e.g. PDE4 activation by PKA phosphorylation), binding of cGMP
(e.g. PDE3 inhibition by cGMP) or cAMP, binding of calcium/calmodulin (PDE1 activation
by calcium /calmodulin), and various protein-protein interactions. Differences in the subcellu-
lar localization of the different PDEs are important for the functional compartmentalization of
cAMP-mediated responses [28].
The interest in PDE1 in the pathogenesis of PKD arose from the facts that PC2 is a TRP
channel with permeability to calcium and that PDE1 is the only PDE family directly regulated
Pde1a mouse knockout
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by calcium and calmodulin [29–32]. The PDE1 family consists of three members encoded by
three different genes. PDE1A and PDE1B have a higher affinity for cGMP than for cAMP,
while PDE1C is equally active for both. PDE1s integrate intracellular calcium levels and cAMP
and cGMP signaling. Phosphorylation of PDE1A and PDE1C by PKA and of PDE1B by cal-
cium/calmodulin-dependent protein kinase II reduces their activity via reduced affinity for
calmodulin and sensitivity to calcium. PDE1 isoforms are dephosphorylated and reactivated
by calcium/calmodulin-dependent protein phosphatase (calcineurin; protein phosphatase 2B).
PDE1 is the most abundant PDE in the distal nephron and collecting duct [33] and catabo-
lizes a cAMP pool under the control of vasopressin and the vasopressin V2 receptor [16, 34].
Therefore we expected that the knockout of Pde1a would result in accumulation of cAMP,
increased PKA-dependent phosphorylation and trafficking of AQP2 to the apical membrane
of collecting duct principal cells, and enhanced urine concentrating capacity. Unexpectedly,
however, we found that the Pde1a deficient mice were less able to concentrate the urine
Fig 6. A) Aortic blood pressures were lower in Pde1aDel15 and Pde1aInsA homozygous mice compared to wild-type mice. B) Echocardiographic studies
showing increased LV ejection fractions in Pde1aDel15 and Pde1aInsA homozygous mice compared to wild-types; RV: Right ventricle; LV: Left ventricle; IVS:
Interventricular septum; PW: Posterior wall C) Measurements of LV mass index using MRI show no significant difference between wild-type and Pde1a
mutant mice. One-way ANOVA with post-hoc Tukey test was used for the statistical analysis.
https://doi.org/10.1371/journal.pone.0181087.g006
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maximally and more capable to excrete an acute water load compared to wild- type controls.
In retrospect, this could have been anticipated because phosphorylation and shuttling of AQP-
2 to the plasma membrane and water permeability in the principal cells of collecting ducts is
under the control of a compartmentalized pool of PDE4D bound to AKAP18delta in aqua-
porin-2 bearing vesicles [18]. Since PDE4 is activated by PKA-mediated phosphorylation,
downregulation of PDE1 and subsequent activation of PKA may account for the increased
PDE4 activity, reduced PKA-dependent phosphorylation of AQP-2, and concentrating defect
observed in our study.
Interest in the role of cAMP and its interaction with calcium as regulators of cell prolifera-
tion dates back almost to its identification as the first known second intracellular messanger
[35]. Remarkably, cAMP inhibits cell proliferation in some cells (e.g. vascular smooth muscle
cells, mesangial cells, endothelial cells, fibroblasts, adipocytes, hepatocytes) while having the
opposite effect in others (thyrocytes, pituitary cells, PC12 pheochromocytoma cells, granulosa
cells, Sertoli cells, neurons, melanocytes) [36, 37]. The mechanisms by which cAMP modulates
cell proliferation are complex, poorly understood and involve interactions with the RAS/RAF/
mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK)
kinase (MEK)/ERK pathway at multiple levels [36, 37]. Cyclic AMP can stimulate or inhibit
cell proliferation via activation or inhibition of ERK, respectively, as well as independently of
this pathway, in a cell and context dependent manner. The type of response depends on the
strength and duration of signaling, the subcellular localization of involved adenylyl cyclases,
A-kinase anchoring proteins, PKA regulatory subunits, phosphodiesterases, and exchange
proteins activated by cAMP (Epacs), and the relative expressions of Rap-1, B-Raf ver‘sus Raf-1,
and B-Raf isoforms, among others.
Previous studies have shown that cAMP stimulates proliferation of PKD-derived tubular
epithelial cells while inhibiting proliferation of wild-type tubular epithelial cells [38–40]. These
contrasting effects of cAMP are likely determined by the level of intracellular calcium, since
the cAMP induced proliferation of ADPKD cells is reversed by activators of L-type calcium
channels or by calcium ionophores. Similarly, the response of wild-type tubular epithelial cells
to cAMP can be switched from inhibition to stimulation of proliferation by lowering free
extracellular calcium or by calcium channel blockers. Inhibition of calcium dependent PI3K
and Akt, which under normal calcium conditions phosphorylate and repress B-Raf, has
been proposed to account for the proliferative effect of cAMP under conditions of calcium
restriction.
The subcellular localization of the different PDEs is crucial for the functional compartmen-
talization of cAMP-mediated responses, and likely explains the lack of significant effect on
total tissue cAMP and cGMP levels detected in PDE1A mutants despite a difference in PDE1
activity. Inhibitory and stimulatory effects of cAMP on cell proliferation have both been linked
to a cAMP pool regulated by PDE3. In mesangial cells, PDE3 and PDE4 inhibitors increase
cAMP levels and activate PKA to a similar extent, but only PDE3 inhibitors block phosphory-
lation of Raf-1 on serine 338, suppress Raf-1 kinase activity and ERK activation, and regulate
proliferation [41, 42]. PDE3, but not PDE4 inhibitors, impede the proliferation of vascular
smooth muscle and endothelial cells [43]. Despite the fact that PDE4 is three times more active
than PDE3 in suspensions of renal cortical tubules, only PDE3 inhibitors suppress the prolifer-
ation of wild-type tubular epithelial cells following administration of folic acid [44]. On the
other hand, only PDE3 inhibitors stimulate proliferation of MDCK cells (often used for cAMP
inducible in vitro cystogenesis) despite the fact that PDE4 inhibitors are more effective in ele-
vating intracellular cAMP levels in these cells [45].
The role of PDE1 in the control of cell proliferation has received less attention. In VSMCs,
PDE1 inhibition or RNA interference of either PDE1A or PDE1C suppresses cell proliferation
Pde1a mouse knockout
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[46–48]. Since inhibition of PDE1 is expected to increase cGMP and cGMP inhibits PDE3, it is
possible that downregulation of PDE1 indirectly affects a specific pool of intracellular cAMP
under the control of PDE3. Interestingly, depletion of either, PDE1A or PDE3A using mor-
pholinos causes pronephric cysts, body curvature, and hydrocephalus in zebrafish [12, 49]. A
recent study has shown that inhibition of PDE1 or PDE3 stimulates the proliferation of
ADPKD cells and that inhibition of PDE1 induces a mitogenic response to vasopressin in nor-
mal human kidney cells similar to the effect of restricting intracellular calcium [50]. These
observations raise the possibility that PDE1 may function as a link connecting changes in
intracellular calcium and the activity of a PDE3 pool controlling cell proliferation. The mild
cystic disease observed in the present study affected the distal nephron (mainly the thick
ascending limb of Henle) and collecting ducts, consistent with the pattern of expression of
vasopressin V2 receptor [51, 52]. The knockout of Pde1a resulted only in a moderate reduction
in PDE1 activity, likely due to redundancy with other PDE1 subfamilies, PDE1C and PDE1B.
We investigated whether Pde1a knockout mice had a cardiac phenotype for several reasons:
i) Cardiovascular manifestations (hypertension, LV hypertrophy, cardiac valvular disease, car-
diomyopathies, aortic root dilatation, arterial aneurysms and dissections, and pericardial effu-
sion) are common causes of morbidity and mortality in ADPKD [22, 23]; ii) PDE1A has been
proposed to play a role in the development of cardiac hypertrophy; iii) The polycystins are
expressed in cardiac and arterial myocytes [53–56]; and iv) Knockdowns of either polycystin in
mice and of PC2 in zebrafish impair myocardial function in the absence of renal cysts [57–60].
PDE1 is one of at least seven PDE families (PDE1 to PDE5, PDE8 and PDE9) present in
mammalian hearts [61]. Reports on its importance relative to other PDE families and the rela-
tive expression of the three PDE1 subfamilies in different animal species have not been consis-
tent (Table A in S1 File)[62–74]. Overall, our findings agree with some but not all published
studies: i) PDE1 accounts for a large proportion of cAMP-PDE activity in the heart [65–67,
70]; ii) The protein expression of PDE1C is much higher than that of PDE1A in the myocar-
dium [63, 64, 67, 72–74]; iii) Therefore, PDE1C is likely more important for cardiac hypertro-
phy than PDE1A; iv) The protein expression of PDE1A is much higher in adult aorta [32, 47,
75]; v) Consistent with this pattern of expression, Pde1a knockout mice in our study had lower
blood pressures and a hyperdynamic circulation with an increased heart rate and ejection frac-
tion. Interestingly, a large gene-centric meta-analysis in 87,736 individuals of European ances-
try has identified an association between the PDE1A locus and diastolic and mean arterial
pressures [76], and mutations of PDE3A resulting in increased PKA–mediated PDE3A phos-
phorylation and gain of function have been found in six families with hypertension and bra-
chydactily syndrome [77]. On the other hand, PDE1 and PDE3 degrade cAMP in the
juxtaglomerular cells thus inhibiting the release of renin and lowering blood pressure [78, 79].
While these observations do not support a role for a deficiency of PDE1A in the cardiac
manifestations of ADPKD, a role for a defect in PDE1A, another PDE1 subfamily or another
PDE family is still possible. In particular, it should be kept in mind that the consequences
of inhibiting PDE1 on PDE3 activity may be different in a wild-type versus a PKD genetic
background. While PDE1A is expressed at low level if at all in cardiac myocytes, it is highly
expressed in the cardiac sinoatrial nodal cells where it regulates pacemaker function. Possibly,
dysregulation of PDE1A activity could contribute to the increased prevalence of atrial fibrilla-
tion reported in ADPKD [80]. While PDE1C and PDE3A inhibitors attenuate cardiac hyper-
trophy and PDE3 inhibitors in the short term enhance LV contractility and overall systolic
function, prolonged inhibition of PDE3 is detrimental because it promotes apoptosis and
hypertrophy of the remaining cardiac myocytes [81].
In summary, PDE1A is strongly expressed in the kidney and the aorta. Knocking out
Pde1a induced mild renal cystic disease and a urine concentrating defect (associated with
Pde1a mouse knockout
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upregulation of PDE4 activity and a decrease in protein kinase A dependent phosphorylation
of aquaporin-2) on a wild-type genetic background and aggravated the renal cystic disease on
a Pkd2WS25/- background. Pkd1a mutants had lower aortic blood pressure and increased LV
ejection fraction without a change in LV mass index, consistent with the high aortic and low
cardiac expression of Pde1a in wild-type mice. These results support an important role of
PDE1A in the renal pathogenesis of ADPKD and regulation of blood pressure.
Supporting information
S1 File. Fig A. Genomic DNA PCR amplification and PvuII-HF restriction endonuclease
digestion of a 792 bp PCR product, showing a 669 and 123 bp fragments in the wild-type, a
777 bp fragment in Del15 and a 793 bp fragment in InsA (A, upper panel). With a longer run
to better separate the upper bands, the lower 123bp band disappears (B, lower panel). Fig B.
Axial and coronal MR images of Pde1a mutant mice at 6 and 12 months of age showing small
renal cysts (arrows). Fig C. Small cysts demonstrated by MRI in a 12 month-old, male wild
type mouse (A) and by histology in 12 month old, female wild-type mouse (B)
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